What has Abingworth invested in recently?

Recent investments include Redx Pharma, Advancell Pty Ltd and Campfield Therapeutics, Inc.. It made 8 investments in the last 12 months.

Where is Abingworth based?

Abingworth is headquartered in London, UK. It has 3 other offices.

How do I contact Abingworth?

Partner names, emails and LinkedIn profiles for Abingworth are on the Capital Atlas Pro and Team plans, which also draft outreach and track replies. Check the stages and cheque size above first, so you pitch a firm that fits your round.

Abingworth

Venture Capital FirmLondon, UKFounded 1973abingworth.com

Est. dry powder

$481.6M

Raised, not yet invested

AUM

$2B

Assets under management

Latest fund

—

Tempe SPV, size not reported

Est. cheque size

$655K–$18.2M

From fund sizes

Deals, last 12 months

Last seen investing Aug 2026

About Abingworth

Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop ideas into products that have an impact on health. Abingworth invests at all stages of development, from start-ups to publicly traded companies, focused on pharmaceutical discovery and development and related enabling technologies. The firm operates out of offices in London, Menlo Park (California), and Boston. In August 2022, Abingworth was acquired by The Carlyle Group.

Type: Venture Capital Firm
Headquarters: London, England, UK
Stages: SeedSeries ASeries BSeries CSeries DSeries ESeries FSeries G+2
Est. cheque size: $655K–$18.2M
Sectors: Diversified, Healthcare, Information Technology
Regions: Europe, North America

Where they invest

From deals and portfolio companies on record

Most frequent rounds

Series A53
Series B50
Series C35
PIPE22
Series D16

Across 234 deals

Portfolio sectors

Biotechnology52
Pharmaceuticals30
Medical Devices & Equipment13
Healthcare2
Healthcare Specialists2

Across 130 companies

Portfolio countries

US65
UK17
Switzerland6
France5
Australia1

Across 130 companies

Recent investments

Newest 5 of 234

Aug 2026
Redx Pharma
Aug 2026 · Series A
Series A$36M5AM Ventures, Redmile Group, NextBio, British Business Bank
Jun 2026
Advancell Pty Ltd
Jun 2026 · Series D
Series D$218.3MT Rowe Price, SV Health Investors, Brandon Capital Partners, Qatar Investment Authority +15
Jun 2026
Campfield Therapeutics, Inc.
Jun 2026 · Series A
Series A$180MVenrock, Novo Holdings, Forbion, Longitude Capital +3
May 2026
Cytospire Therapeutics Limited
May 2026 · Series A
Series A$83M4BIO Capital Partners, Medical Incubator Japan, Servier, Pathway Bioventures +5
Mar 2026
R1 Therapeutics Ltd
Mar 2026 · Series A
Series A$77.5MF-Prime Capital, U.S. Renal Care, Inc., DaVita Venture Group +2

Offices

4 locations

London, England, UKHQ
New York, New York, US
Menlo Park, California, US
Boston, Massachusetts, US

Questions about Abingworth

How much does Abingworth invest per deal?

Based on the size of its funds, Abingworth writes estimated cheques of $655K–$18.2M. Lead cheques usually sit at the top of that range and follow-on cheques lower.

What stages does Abingworth invest in?

Abingworth has invested at Seed, Series A, Series B, Series C, Series D and Series E. Its most frequent rounds on record are Series A, Series B and Series C.

How much capital does Abingworth have left to invest?

Abingworth has an estimated $481.6M in dry powder: capital it has raised but not yet invested.

Similar investors in Europe

Index VenturesUK · Cheque $2.5M–$30M$4B dry powder ForbionNetherlands · Cheque $2.3M–$35.1M$2.4B dry powder European Investment Bank